These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Mora S; Ridker PM Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935 [TBL] [Abstract][Full Text] [Related]
6. [Should we prescribe statins for primary prevention of cardiovascular risk? Rather yes]. Béliard-Lasserre S Rev Prat; 2016 Mar; 66(3):332-334. PubMed ID: 30512650 [TBL] [Abstract][Full Text] [Related]
7. Statins and the cholesterol mortality paradox. Nunes JP Scott Med J; 2017 Feb; 62(1):19-23. PubMed ID: 27889702 [TBL] [Abstract][Full Text] [Related]
8. Statin combination therapy and cardiovascular risk reduction. Toth PP; Farnier M; Tomassini JE; Foody JM; Tershakovec AM Future Cardiol; 2016 May; 12(3):289-315. PubMed ID: 27079178 [TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Pedersen TR Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
12. [Should we prescribe statins for primary prevention of cardiovascular risk? Rather no]. Lecerf JM Rev Prat; 2016 Mar; 66(3):334-337. PubMed ID: 30512651 [TBL] [Abstract][Full Text] [Related]
13. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
14. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. Soran H; Schofield JD; Durrington PN Eur Heart J; 2015 Nov; 36(43):2975-83. PubMed ID: 26242714 [TBL] [Abstract][Full Text] [Related]
15. A review of lipid management in primary and secondary prevention. Dembowski E; Davidson MH J Cardiopulm Rehabil Prev; 2009; 29(1):2-12. PubMed ID: 19158581 [TBL] [Abstract][Full Text] [Related]
16. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487 [TBL] [Abstract][Full Text] [Related]
17. Unmet Needs in LDL-C Lowering: When Statins Won't Do! Krähenbühl S; Pavik-Mezzour I; von Eckardstein A Drugs; 2016 Aug; 76(12):1175-90. PubMed ID: 27456066 [TBL] [Abstract][Full Text] [Related]
18. Central and Brachial Blood Pressures, Statins, and Low-Density Lipoprotein Cholesterol: A Mediation Analysis. Lamarche F; Agharazii M; Nadeau-Fredette AC; Madore F; Goupil R Hypertension; 2018 Mar; 71(3):415-421. PubMed ID: 29295849 [TBL] [Abstract][Full Text] [Related]
19. The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. Soran H; Schofield JD; Durrington PN Curr Opin Lipidol; 2014 Aug; 25(4):239-46. PubMed ID: 24978144 [TBL] [Abstract][Full Text] [Related]
20. [An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients]. Pedro-Botet J; Pintó X Clin Investig Arterioscler; 2016; 28(1):19-30. PubMed ID: 26657098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]